Telix Pharmaceuticals (ASX:TLX) Presentation, FNN Investor Event, April 2018, Sydney

Company Presentations

Key points:

  • Founded November 2015
  • Melbourne-based with team in Europe, US and Japan
  • Located in the Parkville biotech precinct
  • IPO, listed on the ASX in November 2017
  • Raised a total of AUD $58.5m (Seed + IPO)
  • Fully funded for 24 months
  • Mission: to become a leading oncology company in the
  • field of “molecularly-targeted radiation” (MTR)
  • Two major disease focus areas:
  • Neuro-oncology (glioblastoma)
  • Urology (renal / prostate)
For more, watch co-founder and CEO Dr Christian Behrenbruch present.